GW Medical Technologies, LLC' LymPro(TM) Pilot Study Preliminary Results Confirm Ability To Differentiate Probable Alzheimer's Disease (AD) From Other Dementias
10/19/2005 5:09:28 PM
PHOENIX--(BUSINESS WIRE)--July 7, 2005--GW Medical Technologies LLC announced today that its LymPro(TM) Test pilot study far exceeded original expectations and clearly demonstrate the potential to differentiate probable AD patients from other dementia subjects.
The pilot study involved 92 subjects; 34 from healthy participants, 32 with clinically diagnosed probable AD and 26 patients diagnosed with other dementias. The analysis involved the evaluation of 11 independent immune system antigens by flow cytometry, coupled with a sophisticated analytical algorithm for data processing in an effort to clearly define the molecular relationship of these antigens and the test's performance in this regard. The company was elated to find in its preliminary analysis a remarkable 91% co-positivity and 85% co-negativity relationship to the clinical diagnosis of AD.